SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08 Décembre 2023 - 10:05PM
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage
biopharmaceutical company focused on severe rare diseases and
cancer, announced today the closing of its previously announced
underwritten public offering of 10,905,171 shares of its common
stock at a public offering price of $29.00 per share, which
includes the exercise in full by the underwriters of their option
to purchase up to an additional 1,422,413 shares of common stock in
this offering. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and estimated
offering expenses, were approximately $316.25 million.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen
and Company, LLC and Guggenheim Securities, LLC acted as joint
book-running managers for the offering.
An automatic shelf registration statement on Form S-3ASR
(including a prospectus) relating to these securities has been
filed with the Securities and Exchange Commission (SEC) and has
become effective.
The offering was made only by means of a prospectus and
prospectus supplement that form part of the automatic shelf
registration statement. A copy of the final prospectus supplement
and accompanying prospectus relating to the offering has been filed
with the SEC and may be obtained from: Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, or by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1115 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone
at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company
applying a precision medicine approach to developing and delivering
life-changing medicines for people with severe rare diseases and
cancer.
Founded in 2017, SpringWorks has a diversified targeted oncology
pipeline spanning solid tumors and hematological cancers, including
clinical trials in rare tumor types and highly prevalent,
genetically defined cancers. OGSIVEO™, approved in the United
States for the treatment of adult patients with progressing desmoid
tumors who require systemic treatment, is SpringWorks’ first U.S.
Food and Drug Administration (FDA)-approved therapy. SpringWorks’
strategic approach and operational excellence in clinical
development have enabled it to rapidly advance its lead product
candidates into late-stage trials and enter into multiple
collaborations with innovators in industry and academia to unlock
the full potential for its portfolio and create more solutions for
patients with cancer.
SpringWorks Contacts:
Kim DiamondVice President, Communications and Investor
RelationsPhone: 203-561-1646 Email: kdiamond@springworkstx.com
Samantha Hilson SandlerSenior Director, Investor RelationsPhone:
203-461-5501Email: samantha.sandler@springworkstx.com
SpringWorks Therapeutics (NASDAQ:SWTX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024